重组人神经生长因子(重庆科润生物医药)(Recombinant human nerve growth factor(Chongqing Kerun Biologic Pharmaceutical ))

概要

基本信息

药物类型

生长因子

别名-

靶点-

作用机制-

治疗领域

眼部疾病其他疾病

在研适应症

神经营养性角膜炎干眼症

非在研适应症-

原研机构

重庆科润生物医药研发有限公司

在研机构

重庆科润生物医药研发有限公司

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)临床1期

特殊审评-

登录后查看时间轴

关联

2

项与重组人神经生长因子(重庆科润生物医药) 相关的临床试验

CTR20240851 / Recruiting临床1期

重组人神经生长因子滴眼液治疗神经营养性角膜炎的随机、双盲、安慰剂平行对照、多中心、Ib 期临床试验

主要目的以安慰剂为对照，初步评价不同剂量rhNGF滴眼液治疗神经营养性角膜炎（NK）的有效性。次要目的 1. 为rhNGF滴眼液后续临床试验的给药剂量提供依据。 2. 评价rhNGF滴眼液的全身药代动力学（PK）特征及免疫原性。 3. 初步评价不同剂量rhNGF滴眼液治疗神经营养性角膜炎（NK）的安全性。

开始日期2024-05-20

申办/合作机构

重庆科润生物医药研发有限公司

CTR20230580 / Active, not recruiting临床1期

重组人神经生长因子滴眼液在中国健康成年受试者中单次给药/多次给药的安全性、耐受性及药代动力学 Ia 期临床试验

1、评价重组人神经生长因子滴眼液在中国健康受试者中单、多次给药后的安全性和耐受性。2、评价重组人神经生长因子滴眼液在中国健康受试者中单、多次给药后的药代动力学特性。3、评价重组人神经生长因子滴眼液在中国健康受试者中单、多次给药后的免疫原性。

开始日期2023-05-08

申办/合作机构

重庆科润生物医药研发有限公司

100 项与重组人神经生长因子(重庆科润生物医药) 相关的临床结果

登录后查看更多信息

100 项与重组人神经生长因子(重庆科润生物医药) 相关的转化医学

登录后查看更多信息

100 项与重组人神经生长因子(重庆科润生物医药) 相关的专利（医药）

登录后查看更多信息

4

项与重组人神经生长因子(重庆科润生物医药) 相关的文献（医药）

2024-10-20·Ocular Immunology and Inflammation

Effect of Topical Recombinant Human Nerve Growth Factor on Corneal Epithelial Regeneration in Refractory Epithelial Keratopathy

Article

作者: Karakus, Sezen ; Zhu, Xi ; Tunc, Ugur ; Dai, Xi

PURPOSETo report the effect of topical application of recombinant human nerve growth factor (rhNGF) eye drops on corneal epithelial regeneration in patients with refractory epitheliopathy.METHODSA retrospective chart review was conducted on patients treated with topical rhNGF for refractory epithelial keratopathy due to stage I neurotrophic keratitis (NK). Data regarding demographics and ocular/systemic past medical history was extracted from patient charts. Visual acuity and corneal staining scores were recorded at baseline and subsequent follow-up visits at 8 weeks and 3 months. Measurements from the worse eye were used to compare before and after treatment values.RESULTSWe identified 14 patients (median age 68 years, 21% male) who received rhNGF treatment for refractory epithelial keratopathy. After an 8-week treatment with topical rhNGF, the median corneal staining score in the worse eye improved from 4 to 1 (p = 0.001). All patients showed at least one-grade improvement in corneal staining at 8 weeks, with sustained effect in seven patients at 3 months. A better response was observed in eyes with post-radiation epithelial keratopathy, LASIK, and Sjogren's disease. Those with chronic use of other topical treatments and uncontrolled diabetes mellitus demonstrated incomplete responses. Eight patients reported mild-to-moderate ocular discomfort from drop application that fully resolved after completion of treatment.CONCLUSIONSTopical rhNGF was effective and safe for refractory epithelial keratopathy in our small cohort, but sustained effects were seen only in certain etiologies for up to 3 months. Further studies are needed for optimal dosing and duration based on underlying causes.

1990-12-01·Experimental Neurology2区 · 医学

Trophic actions of recombinant human nerve growth factor on cultured rat embryonic CNS cells

2区 · 医学

Article

作者: Donald L. Price ; Beat Knüsel ; Franz Hefti ; Vassilis E. Koliatsos ; Louis E. Burton ; Frank M. Longo ; William C. Mobley

NGF is a neurotrophic factor for basal forebrain cholinergic neurons and may serve to counteract the cholinergic deficits that are observed in Alzheimer's disease. Prior to the introduction of clinical trials, it is essential that recombinant human NGF (rhNGF) be produced and that its actions on target cells in the CNS be demonstrated. We prepared rhNGF and examined its actions on fetal rat brain neurons in culture including, in particular, the cholinergic neurons of the basal forebrain. rhNGF was more potent in increasing choline acetyltransferase (ChAT) activity in septal cultures than NGF purified from mouse salivary glands (mNGF). ED50s of the beta-NGF dimers were 4.9 pM for rhNGF and 12.4 pM for mNGF. The maximal ChAT activity response was achieved at approximately 35 pM with both NGFs and their efficacies were not significantly different. The two NGFs were not additive in effect. Identical to the results with mNGF, rhNGF strongly enhanced the intensity of ChAT immunostaining in septal cultures. Neither rhNGF nor mNGF affected the appearance of the cultures under phase-contrast illumination. Survival of cells at very low plating density on polyornithine/laminin-coated culture dishes was not affected by rhNGF or mNGF. Protein content and the uptake of GABA were also unaffected. At concentrations of up to 10 micrograms/ml, rhNGF did not significantly increase uptake of dopamine into cultures of ventral mesencephalon. We conclude that rhNGF produces potent and selective actions on cholinergic neurons of the basal forebrain as previously shown for mNGF.

1990-01-01·Leukemia Research4区 · 医学

Usefulness of neutral red uptake method for investigation of the effects of recombinant hemopoietic growth factors on leukemic blasts proliferation

4区 · 医学

Article

作者: Junichi Tsukada ; Shyozo Chiba ; Masahiro Misago ; Sumiya Eto ; Makoto Kikuchi ; Tadatsugu Sato ; Susumu Oda

By a colorimetric assay with dye (neutral red), the effects of recombinant human hemopoietic growth factors (rhG-CSF, rhGM-CSF, rhIL-3 and rhEPO) on the proliferation of leukemic blasts in vitro were investigated. Leukemic blasts were obtained from eight patients with acute myeloid leukemia (AML) (M1: two cases, M3: two cases, M4: four cases) and from four patients with acute lymphoid leukemia (ALL) (L2: four cases). It was shown that rhG-CSF, rhGM-CSF and rhIL-3 stimulated the blast proliferation in most cases of AML, although the degree and pattern of responses showed a striking variability in different patients. Moreover, rhGM-CSF and rhIL-3 also stimulated the leukemic blasts from some cases of ALL. No clear morphological modification providing evidence for terminal differentiation was observed when assessed by Wright stain. On the other hand, rhEPO did not have any stimulating effects on leukemic blasts in all cases. These results indicate the necessity of investigating the responses of leukemic blasts to hemopoietic growth factors in each patient prior to clinical use of such factors. For this assay, neutral red uptake method is useful because of its simplicity, rapidity, precision and convenience for handling a large volume of materials.

100 项与重组人神经生长因子(重庆科润生物医药) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
神经营养性角膜炎	临床1期	中国	重庆科润生物医药研发有限公司	2023-05-08
干眼症	临床前	中国	重庆科润生物医药研发有限公司	2022-10-24